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Abstract
Background: Community-acquired pneumonia (CAP) is the most frequent infection-related cause of
death. The reference standard to diagnose CAP is a new infiltrate on chest radiograph in the presence of
recently acquired respiratory signs and symptoms. This study aims to evaluate the diagnostic and
prognostic accuracy of clinical signs and symptoms and laboratory biomarkers for CAP.
Methods: 545 patients with suspected lower respiratory tract infection, admitted to the emergency
department of a university hospital were included in a pre-planned post-hoc analysis of two controlled
intervention trials. Baseline assessment included history, clinical examination, radiography and
measurements of procalcitonin (PCT), highly sensitive C-reactive protein (hsCRP) and leukocyte count.
Results: Of the 545 patients, 373 had CAP, 132 other respiratory tract infections, and 40 other final
diagnoses. The AUC of a clinical model including standard clinical signs and symptoms (i.e. fever, cough,
sputum production, abnormal chest auscultation and dyspnea) to diagnose CAP was 0.79 [95% CI, 0.75–
0.83]. This AUC was significantly improved by including PCT and hsCRP (0.92 [0.89–0.94]; p < 0.001). PCT
had a higher diagnostic accuracy (AUC, 0.88 [0.84–0.93]) in differentiating CAP from other diagnoses, as
compared to hsCRP (AUC, 0.76 [0.69–0.83]; p < 0.001) and total leukocyte count (AUC, 0.69 [0.62–0.77];
p < 0.001). To predict bacteremia, PCT had a higher AUC (0.85 [0.80–0.91]) as compared to hsCRP (p =
0.01), leukocyte count (p = 0.002) and elevated body temperature (p < 0.001). PCT, in contrast to hsCRP
and leukocyte count, increased with increasing severity of CAP, as assessed by the pneumonia severity
index (p < 0.001).
Conclusion: PCT, and to a lesser degree hsCRP, improve the accuracy of currently recommended
approaches for the diagnosis of CAP, thereby complementing clinical signs and symptoms. PCT is useful in
the severity assessment of CAP.
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Background
Community-acquired pneumonia (CAP) is the major
infection-related cause of death in developed countries
[1,2]. The reference standard to diagnose CAP is a new
infiltrate on chest radiograph in the presence of recently
acquired respiratory signs and symptoms [2-4]. These
include cough, increased sputum production, dyspnea,
fever and abnormal auscultatory findings [5]. Unfortu-
nately, clinical findings do not reliably predict radiologi-
cally confirmed pneumonia [6]. Especially elderly people
often present with atypical symptoms and without fever
[7]. Physicians, especially in primary care, may not per-
form radiography and rely on the patient's history and
physical examination [8].
The differential diagnosis of CAP includes several non-
infectious causes, including pulmonary embolism, malig-
nancy and congestive heart failure, among others [9]. The
presence of a non-infectious differential diagnosis is usu-
ally suspected only after failure of antibiotic therapy, with
the ensuing risks related to untreated, potentially life-
threatening non-bacterial disease [10]. Conversely, a
delay of antibiotic treatment of more than 4 hours after
hospital admission is associated with increased mortality
[11]. Hence, both a rapid diagnosis of CAP and an accu-
rate differentiation from viral respiratory illnesses and
non-infectious causes has important therapeutic and
prognostic implications [12].
We recently reported the results of 2 intervention trials
that assessed the value of procalcitonin (PCT) in guiding
antibiotic treatment decisions in consecutive patients
with suspected lower respiratory tract infections [13,14].
In the present pre-planned, post-hoc analysis of the 2
datasets containing detailed data from 545 patients, we
evaluated three clinically relevant questions. To mirror an
approach often done in primary care, we first evaluated
the diagnostic accuracy of different parameters for diag-
nosing CAP solely based on history, clinical examination
and laboratory parameters without radiography. To mir-
ror an approach in an emergency department, we sec-
ondly compared different parameters to differentiate
bacterial CAP from other differential diagnoses in patients
with suspected CAP based on recently acquired respira-
tory signs and an infiltrate in chest radiograph. Third, we
estimated the accuracy of different parameters to predict
bacteremia and the severity of CAP.
Methods
Setting and Study Population
Data from two randomized prospective studies with a
total of 545 patients with suspected lower respiratory tract
infections, who presented to the emergency department
of a 950-bed tertiary care center in Basel (Switzerland),
were combined in a preplanned post-hoc analysis. The
design of the two studies was similar. A complete descrip-
tion has been reported elsewhere [13,14]. In brief, consec-
utive patients with clinically suspected lower respiratory
tract infections [13] and radiologically confirmed CAP
[14], respectively, admitted from December 2002 until
April 2003 (n = 243) and from November 2003 through
February 2005 (n = 302) to the University Hospital were
analyzed. The primary endpoint of the two studies was to
evaluate the prescription and duration of antibiotic use in
patients randomly assigned to PCT-guidance (275
patients) as compared to standard recommended guide-
lines (270 patients). Patients had to be > 18 years with a
suspected lower respiratory tract infection (i.e. CAP, acute
exacerbations of chronic obstructive pulmonary disease
[AECOPD], acute bronchitis, asthma exacerbation) as
principal diagnosis on admission. CAP was defined by the
presence of one or several of the following recently
acquired respiratory signs and symptoms: cough, sputum
production, dyspnea, core body temperature ≥ 38.0°C,
auscultatory findings of abnormal breath sounds and
rales, leukocyte count > 10 or < 4 × 109 cells L-1 and an
infiltrate on chest radiograph [2]. AECOPD was defined as
a FEV1/FVC ratio below 70% and the severity of AECOPD
was defined as proposed[15] Acute bronchitis was defined
as acute onset cough of 2 to 14 days with or without spu-
tum production in the absence of an underlying lung dis-
ease or focal chest signs and infiltrates on chest
radiography, respectively [16]. Asthma was defined as epi-
sodic symptoms of airflow obstruction, at least partially
reversible as assessed by lung function tests [17]. Excluded
were patients with cystic fibrosis or active pulmonary
tuberculosis; hospital-acquired pneumonia and severely
immunocompromised patients (e.g. AIDS, febrile neutro-
penia after chemotherapy).
All patients were examined on admission to the emer-
gency department by a resident supervised by a board-cer-
tified specialist in internal medicine. Baseline assessment
included clinical data and vital signs, comorbid condi-
tions, and routine blood tests. Chest radiographs were
screened by the physician in charge. A senior radiologist,
unaware of clinical and laboratory findings, reviewed all
chest radiographs. The Pneumonia Severity Index (PSI)
and the CURB65 score were calculated as described
[18,19].
The patients' functional status was assessed using a visual
analogue scale, ranging from 0 (feeling extremely ill) to
100 (feeling completely healthy), and by a quality of life
(QoL) questionnaire for patients with respiratory illnesses
[12].
Both studies were approved by the local Ethics Committee
(Ethikkommission beider Basel, "EKBB") and all partici-
pants gave written informed consent to participate in theBMC Infectious Diseases 2007, 7:10 http://www.biomedcentral.com/1471-2334/7/10
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study. After publication of the novel rules [20], the second
trial was registered in the Current Controlled Trials Data-
base [ISRCTN04176397] [21].
Definition of the presence and absence of a bacterial 
cause in suspected CAP
A microorganism was defined as causing agent, if detected
in respiratory specimens (sputum or bronchoalveolar lav-
age fluid [BAL]), blood, or both, excluding normal skin or
mucosal flora. Only relevant microorganisms cultured
from representative sputum specimens according to Mur-
ray's criteria were considered, i.e., > 25 leukocytes and <
10 epithelial cells per high power field. Identical microor-
ganisms cultured in a patient from both sputum and
bronchoalveolar lavage fluid were considered only once.
We searched for Legionella pneumophila antigen in urine
(Legionella now Binax, Portland, ME, USA), by culture or
by polymerase chain reaction (PCR) from bronchoalveo-
lar lavage fluid. Mycoplasma pneumoniae was detected by
culture or PCR in BAL fluid. Chlamydia pneumoniae was
identified by PCR in BAL fluid. As used to define bacterial
CAP in a previous study [22] clinically relevant bacterial
CAP was considered to be absent if an alternative cause for
pulmonary infiltrate was established without bacterial
growth in culture results or if the patient completely
recovered from fever, infiltrates, and leukocytosis without
appropriate antimicrobial therapy.
Measurement of Biomarkers
PCT was measured within one hour after blood sampling
using 20 to 50 µL of plasma or serum by a time-resolved
amplified cryptate emission (TRACE) technology assay
(Kryptor® PCT, Brahms AG, Hennigsdorf, Germany), as
described [13]. The assay has a functional assay sensitivity
of 0.06 µg/L, which is about four-fold above mean normal
levels [23]. Highly-sensitive C-reactive protein (hsCRP)
was measured in heparin plasma on a Hitachi Instrument
917 (Roche Diagnostics, Rotkreuz, Switzerland; using rea-
gents provided by Wako Chemicals GmbH, Neuss, Ger-
many). Levels that were non-detectable were assigned a
value equal to the lower limit of detection for the assay.
In 74 and 80 patients, PCT and CRP, respectively, were
measured not only on admission, but also after 6 to 24
hours. This follow-up measurement was foreseen in the
study protocols for all cases with initial uncertainty. In
these patients, the peak values were used for the analyses.
Statistical Analysis
Discrete variables are expressed as counts (percentage)
and continuous variables as means ± standard deviation
(SD), unless stated otherwise. Frequency comparison was
done by chi-square test. Two-group comparison of nor-
mally distributed data was performed by Student's t-test.
For multigroup comparisons, one-way analysis of vari-
ance (ANOVA) with least square difference for posthoc
comparison was applied. For data not normally distrib-
uted, the Mann-Whitney-U test was used if only two
groups were compared and the Kruskal-Wallis one-way
analysis of variance was used if more than two groups
were being compared. Correlation analyses were per-
formed by using Spearman rank correlation. Standard def-
initions of sensitivity, specificity, and likelihood ratio
(LR) were used [24,25]. We constructed receiver operating
characteristic (ROC) curves and determined the areas
under the receiver operating characteristic curve (AUC), as
previously described [26-28]. All statistical tests were 2-
tailed. P < 0.05 was considered significant. Statistical
packages used were MedCalc for Windows, (version
7.2.1.0., Mariakerke, Belgium) and STATA, version 8.0
(Stata, College Station, USA).
Results
Baseline characteristics of the patients
Baseline characteristics of the 545 patients on admission
are shown in Table 1.
Temperature > 37.9°C was present in 290 (53.2%)
patients. The typical triad of cough, fever and dyspnea, as
reported by the patient, was present in 230 (42.2%) of
cases. Abnormal chest auscultation was present in 469
(86.1%) patients, rales in 394 (72.3%) patients.
396 (72.7%) patients had an infiltrate on chest radiogra-
phy and were on admission classified as having CAP. In
373 (68.4%) CAP was confirmed as final diagnosis at fol-
low-up. Conversely, 23 (4.2%) patients with infiltrate on
chest radiography had a final diagnosis other than lower
respiratory tract infection. This included 20 (3.7%)
patients with a non-infectious final diagnosis, i.e. conges-
tive heart failure (4), pulmonary embolism (4), cryp-
togenic organizing pneumonia (2), malignancy (5),
unknown interstitial pneumopathy (2), pleural effusion
of unknown etiology (1), polyserositis (1), Wegener gran-
ulomatosis (1). In addition, 3 patients with infiltrate on
chest radiography had other infectious diagnoses, namely,
urosepsis (1), endocarditis (1), deep surgical site infection
of the sternum (1). 17 (3.1%) patients without infiltrate
on chest radiography had a diagnose other than lower res-
piratory tract infections.
Microbiology
Overall, in the 373 patients with the final diagnosis of
CAP, 11.3% of blood cultures and 21.5% of cultures from
respiratory secretions were positive. Overall the responsi-
ble pathogen in patients with CAP could be cultured in 98
(26.3%) of patients. The causative microorganisms are
listed in Table 2. The most frequently isolated microor-
ganism was Streptococcus pneumoniae.BMC Infectious Diseases 2007, 7:10 http://www.biomedcentral.com/1471-2334/7/10
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Diagnostic accuracy for discriminating CAP from other 
lower respiratory tract infection without radiography
To mirror an approach occasionally done in primary care,
we evaluated the diagnostic accuracy for diagnosing CAP
(n = 373) solely based on history, clinical examination
and laboratory parameters without ascertainment by radi-
ography.
As shown in Figure 1a, PCT and hsCRP yielded the highest
discriminative value to diagnose CAP. In this setting, the
difference between hsCRP and PCT was not significant (p
= 0.36). In comparison, commonly used clinical signs
such as fever (temperature > 37.9°C), leukocyte count, an
abnormal chest auscultation, sputum production, dysp-
nea and cough had all lower discriminative values (p for
all comparisons of PCT and hsCRP, respectively, with
other parameters < 0.001).
A clinical model including fever, cough, sputum produc-
tion, abnormal chest auscultation and dyspnea [5] had an
AUC of 0.79 (95% CI, 0.75–0.83). The inclusion of
hsCRP in this clinical model increased this AUC value to
0.90 (95% CI, 0.87–0.93; p < 0.001). The inclusion of
PCT increased the AUC of the clinical model to 0.88
(0.85–0.91; p < 0.001). The clinical model with hsCRP
was not significantly different as compared to that with
PCT (p = 0.18). A clinical model including both hsCRP
and PCT had an AUC of 0.92 (95% CI, 0.89–0.94), which
was significantly better as compared to a model using PCT
or hsCRP alone (p < 0.001 for both comparisons), respec-
tively.
The multilevel likelihood ratios for hsCRP and PCT levels
in diagnosing CAP are shown in Table 3.
All results were similar after age stratification for patients
> 75 years.
Diagnostic accuracy for radiographically defined CAP
Herein, we evaluated the diagnostic accuracy for differen-
tiating radiographically and clinically diagnosed CAP
from other differential diagnoses of CAP.
First, to separate the 20 (3.7%) patients with an infiltrate
on chest radiography and a non-infectious final diagnosis
from the 373 confirmed CAP patients, the diagnostic
accuracy of PCT was higher as compared to hsCRP (p =
0.04), leukocyte count (p = 0.01), body temperature (p =
0.001), chest auscultation (p < 0.001) and sputum pro-
duction (p < 0.001) (Figure 1b).
Second, 24 (6.4%) of the 373 patients with the final diag-
nosis of CAP fulfilled the criterion of full recovery from
fever, infiltrates, and leukocytosis without any antimicro-
bial therapy. As suggested as definition for bacterial CAP
in a previous study [22] these 24 patients were thus classi-
fied as not having pneumonia of clinically relevant bacte-
rial origin. After adding these 24 patients to the 20
patients with a proven non-infectious origin of chest infil-
trates, the diagnostic accuracy for PCT was also higher as
compared to hsCRP (p < 0.001), leukocyte count (p <
0.001) and body temperature (p < 0.001, Figure 1c).
The multilevel likelihood ratios for hsCRP and PCT levels
in this setting are shown in Table 4.
Table 1: Baseline Characteristics of the 545 Patients*
Characteristic
Age – years 67.1 ± 18.0
Male sex – no. (%) 314 (62.6)
Smoking status
- Current smoker – no. (%) 135 (24.8)
- Packyears history in smokers 40.0 ± 24.9
Antibiotic pretreatment (%) 110 (20.2)
Underlying disease – no. (%)
- Coronary artery disease 156 (28.6)
- Hypertensive heart disease 95 (17.4)
- Congestive heart failure 34 (6.2)
- Peripheral vascular disease 39 (7.2)
- Cerebrovascular disease 25 (4.6)
- Renal dysfunction 121 (22.2)
- Liver disease 43 (7.9)
- Diabetes mellitus 93 (17.1)
- Neoplastic disease 65 (11.9)
Symptoms – no. (%)
- Cough 497 (91.2)
- Sputum 390 (71.6)
- Dyspnea 392 (71.9)
Signs– no. (%)
- Rales 394 (72.3)
Final diagnoses – no. (%)
- CAP 373 (68.4)
- Other respiratory tract infections 132 (24.2)
- Asthma 13 (2.4)
- Acute bronchitis 59 (10.8)
- Acute exacerbation of COPD 60 (11.0)
- Others 40 (7.3)
- With infiltrate on chest radiography 23 (4.2)
- Without infiltrate on chest radiography 17 (3.1)
PSI in patients with CAP – points 96.4 ± 36.0
PSI class – no. (%)
- I, II and III 162 (43.4)
- IV 150 (40.2)
- V 61 (16.4)
Laboratory parameters
hsCRP (mg/L) (mean; median (range)) 127.9; 103.4 (0.5–512)
PCT (µg/L) (mean; median (range)) 3.1; 0.32 (0.02–234.7)
Leukocyte count (×109/L) 12.9 ± 6.7
*Plus-minus values are means ± SD. Because of rounding, percentages 
may not sum to 100. COPD denotes chronic obstructive pulmonary 
disease, PSI pneumonia severity index, CAP community-acquired 
pneumonia, hsCRP highly-sensitive C-reactive protein, PCT 
procalcitonin.BMC Infectious Diseases 2007, 7:10 http://www.biomedcentral.com/1471-2334/7/10
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Diagnostic accuracy to predict bacteremia
Of the 373 patients with the final diagnosis of CAP, 42
(11.3%) had positive blood cultures. Thus, a positive
blood culture had a sensitivity of 11.3 percent to predict
CAP. To predict bacteremia in patients with CAP, PCT had
a higher AUC as compared to hsCRP (p = 0.01), leukocyte
count (p = 0.002) and elevated body temperature (p <
0.001) (Figure 1d). The multilevel likelihood ratios for
hsCRP and PCT levels in diagnosing bacteremia in
patients with CAP in this setting are shown in Table 5.
Accuracy to predict severity of CAP
PCT levels increased with increasing severity of CAP, clas-
sified according to the PSI score (p < 0.001). This increase
was more pronounced as compared to total leukocyte
count (p = 0.08), C-reactive protein (p = 0.90), body tem-
perature (p = 0.42), and the visual analogue scale (p =
0.21) (Figure 2). Results for the CURB65 score were simi-
lar (data not shown). PCT levels in patients with mild
CAP (defined as PSI class I to III) were significantly lower
as compared to patients with severe CAP (defined as PSI
class IV and V; p < 0.001). This difference was not signifi-
cant for C-reactive protein (p = 0.96), total leukocyte
count (p = 0.25), body temperature (p = 0.48) and the vis-
ual analogue scale (p = 0.06).
Discussion
Our data show that clinical signs and symptoms routinely
used and recommended to screen and to establish the
diagnosis of CAP are of limited value. Both, PCT and
hsCRP improve the diagnostic value of the clinical assess-
ment. On admission, PCT has the highest diagnostic accu-
racy in differentiating radiologically confirmed CAP from
other differential diagnoses, to predict the later finding of
bacteremia and to assess the severity of CAP.
According to most guidelines, an infiltrate in chest radio-
graph is mandatory for the diagnosis of CAP. However, in
the setting of primary care, radiography may often not be
performed [8]. Instead, based on the clinical suspicion
and in view of the severe consequences of delayed antibi-
otic therapy, physicians have a low threshold to initiate
antibiotic therapy in presumed CAP [29,30]. Obviously,
the timely clinical evaluation of patients with symptoms
suggestive of CAP is important to estimate the pretest
probability for the disease, to assess the severity of illness,
and to start appropriate antimicrobial therapy. However,
as confirmed by our data, most routinely used clinical
parameters, alone or in combination, have poor diagnos-
tic accuracies to predict CAP. Similar clinical signs and
symptoms are caused by acute bronchitis, AECOPD,
asthma exacerbations and non-infectious diagnoses such
as congestive heart failure or atelectasis. In addition, the
interpretation of the clinical assessment lacks standardiza-
tion and validation and is, therefore, prone to interob-
server variability [31,32]. We are aware that the lack of
diagnostic accuracy of history and clinical examination
has been reported [5,31]. However, despite their known
limitations, clinical signs are daily used for decision mak-
ing in clinical routine. Herein, we propose the use of
biomarkers to complement and improve clinical assess-
ment.
Table 2: Identified microorganisms in patients with CAP (n = 373)
Respiratory secretions Blood cultures
Overall positive – no. (%) 80 (21.5) 42 (11.3)
Gram-positive organisms 39 36
Streptococcus pneumoniae 32 33
Streptococcus milleri 20
Staphylococcus aureus 43
Enterococcus species 1 0
Gram-negative organisms 34 6
Moraxella catarrhalis 30
Haemophilus influenzae 90
Pseudomonas species 13 2
Klebsiella species 7 2
Neisseria meningitidis 02
Morganella morganii 1 0
Enterobacteriaceae 1 0
Atypical pathogens 7 0
Mycoplasma pneumoniae 20
Legionella pneumophila ‡5 0
‡ Legionella pneumophilia was detected by urinary antigen in 4 patients.BMC Infectious Diseases 2007, 7:10 http://www.biomedcentral.com/1471-2334/7/10
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As shown by our data, together with a careful clinical
assessment and radiology, biomarkers like PCT and
hsCRP can significantly increase diagnostic accuracy for
the diagnosis of CAP. One might argue that the diagnosis
of bronchitis, CAP and AECOPD should be clinically evi-
dent as should the indication for antibiotic therapy. How-
ever, despite the presence of excellent and recent
guidelines, the implementation into clinical routine
namely for these "evident diseases" is insufficient. Thus in
our opinion, as a biomarker PCT becomes especially val-
uable as a powerful tool to better complement and imple-
ment these guidelines, as shown in our intervention
studies.
In the setting of an emergency department of a hospital,
most patients presenting with symptoms of respiratory
tract infection will receive a chest radiograph. In the pres-
ence of a new infiltrate, a bacterial etiology is usually
assumed. However, bacterial causes must be differentiated
from other, non-infectious or viral etiologies, which can
be challenging. We demonstrate that the routinely used
clinical parameters in radiographically defined CAP miss
Receiver operating characteristics curves (ROC) of different parameters for the diagnosis of pneumonia Figure 1
Receiver operating characteristics curves (ROC) of different parameters for the diagnosis of pneumonia. a diag-
nostic accuracy to predict CAP without chest radiography: Primary care approach. b diagnostic accuracy to predict radio-
graphically suspected CAP (control group (n = 20) includes other non-infectious diagnoses initially diagnosed as CAP): 
Emergency department approach. c diagnostic accuracy to predict radiographically suspected CAP (control group (n = 44) 
includes other non-infectious diagnoses initially diagnosed as CAP (n = 20) plus patients without a clinically relevant bacterial 
etiology of CAP (n = 24). d diagnostic accuracy to predict bacteremic CAP. Values show areas under the ROC curve with 95% 
confidence intervals. Chest auscult. denotes abnormal chest auscultation; CRP C-reactive Protein; PCT procalcitonin.
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the diagnostic accuracy to differentiate between bacterial
and non-bacterial CAP. PCT, better than hsCRP, improves
diagnostic accuracy to distinguish bacterial CAP from
non-infectious or non-bacterial causes, respectively. Thus,
if a patient shows an infiltrate on chest radiograph in the
presence of acute respiratory symptoms and very low PCT
levels (< 0.1 µg/L), clinicians should actively seek for an
alternative diagnosis to bacterial pneumonia.
Positive blood cultures in CAP patients correlate with
adverse outcome and, thus, a rapid initiation of antimi-
crobial treatment is pivotal [33-35]. However, results
from microbiological cultures of body fluids are only
available after 24 to 48 hours, which can be problematic
for clinical practice. A PCT cut-off of 0.25 µg/L had a 98%
sensitivity to detect bacteremia. PCT may thus provide val-
uable and faster information about severity of disease
long before blood culture results become available.
Accordingly, PCT better mirrored the severity of CAP clas-
sified by the PSI, as compared to hsCRP levels, leukocyte
counts or the visual analogue scale, which were unable to
distinguish mild from more severe pneumonia.
Several limitations of our study merit consideration. First,
results of two studies were combined introducing the pos-
sibility of a selection bias, although in both studies the
primary endpoint was similar. Second, since antibiotics
were withheld based on PCT levels, this may have intro-
duced a bias to the favor of PCT. Conversely, cure of CAP
under antibiotic therapy may falsely have been considered
as proof of bacterial etiology in a considerable proportion
of patients who indeed had a non-bacterial etiology.
Third, our results may not apply for immunosuppressed
patients and other clinical settings or sites of infection,
especially localized or fungal pulmonary infections such
as empyema and aspergillosis. However, these are unlike
conditions in outpatients presenting with lower respira-
tory tract infections. The diagnostic accuracy of PCT in
patients with immunosuppression or hospital-acquired
pneumonia has to be evaluated in future studies. These
patients were excluded for safety reasons. Forth, interob-
server variation in the clinical evaluation of patients with
CAP has not been examined. Other studies have revealed
considerable interobserver variability in the recording and
evaluation of symptoms. Fifth, we only assessed total leu-
kocyte count and not band forms. However, in recent
studies, the superiority of hsCRP and PCT as compared to
leukocyte count and band counts has been shown
[25,36,37]. Finally, the rate of microbiologically docu-
mented CAP in our study population was rather low, lim-
iting information about the diagnostic accuracy of PCT for
the etiological diagnoses. We did not routinely perform
serology or PCR or culture in blood and respiratory secre-
tions for Mycoplasma pneumoniae and Chlamydia pneumo-
Table 4: Multilevel likelihood ratios for hsCRP and PCT to diagnose CAP in patients with an infiltrate on chest radiography
N (%) Sensitivity Specificity LR + LR -
PCT (µg/L)
> 0.1 349 (89) 0.90 0.39 1.48 0.25
> 0.25 280 (71) 0.74 0.74 2.83 0.35
> 0.5 217 (55) 0.57 0.83 3.30 0.52
> 1.0 163 (41) 0.43 0.87 3.31 0.65
hsCRP (mg/L) N (%) Sensitivity Specificity LR + LR -
> 40 349 (89) 0.89 0.17 1.07 0.65
> 50 339 (86) 0.87 0.26 1.17 0.52
> 100 265 (67) 0.69 0.61 1.76 0.51
> 200 136 (34) 0.36 0.91 4.14 0.70
Table 3: Multilevel likelihood ratios for hsCRP and PCT to diagnose CAP without chest radiography
N (%) Sensitivity Specificity LR + LR -
PCT (µg/L)
> 0.1 406 (75) 0.90 0.59 2.22 0.16
> 0.25 300 (55) 0.74 0.85 4.87 0.31
> 0.5 225 (41) 0.57 0.93 8.21 0.46
> 1.0 167 (31) 0.43 0.96 10.57 0.59
hsCRP (mg/L) N (%) Sensitivity Specificity LR + LR -
> 40 413 (76) 0.89 0.52 1.86 0.22
> 50 384 (70) 0.87 0.65 2.44 0.21
> 100 281 (52) 0.69 0.86 4.94 0.36
> 200 141 (26) 0.36 0.96 8.83 0.67BMC Infectious Diseases 2007, 7:10 http://www.biomedcentral.com/1471-2334/7/10
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niae. Moreover, search for Streptococcus pneumoniae
antigen in urine was not routinely done. However, using
representative respiratory secretions and blood cultures
the rate of documented bacterial CAPs in our study was
very similar to the one in different recent studies [38] or
[39].
Strengths of our study are first that the study population
included a relatively diverse group of patients with lower
respiratory tract infections. Second, we did not include
clinically unrealistic control patients without suspected
infection, but only patients with a high pretest probability
of CAP, covering the spectrum that is likely to be encoun-
tered in the future use of these tests [40]. Our study is thus
based on a real-life patient sample to closely resemble
clinical practice in a emergency room setting. As com-
pared to primary care setting, our study cohort might have
a higher pretest probability for pneumonia which might
bias our question about the diagnostic accuracy of PCT for
diagnosing CAP solely based on history, clinical examina-
tion and laboratory parameters without radiography, an
approach occasionally done in primary care.
PCT as compared to hsCRP and leukocyte count in different severities of CAP Figure 2
PCT as compared to hsCRP and leukocyte count in different severities of CAP. PCT denotes procalcitonin, CRP 
highly-sensitive C-reactive protein, PSI pneumonia severity index. Diamonds denote means, squares SEM and whiskers 1.96 
SEM of the combined data. The scatterplots represent all values.
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Table 5: Multilevel likelihood ratios for hsCRP and PCT to diagnose bacteremia in patients with CAP
N (%) Sensitivity Specificity LR + LR -
PCT (µg/L)
> 0.1 336 (90) 1.0 0.11 1.12 < 0.01
> 0.25 274 (74) 0.98 0.29 1.38 0.08
> 0.5 213 (57) 0.93 0.48 1.78 0.14
> 1.0 160 (43) 0.86 0.63 2.32 0.22
hsCRP (mg/L) N (%) Sensitivity Specificity LR + LR -
> 40 331 (89) 0.91 0.12 1.03 0.79
> 50 323 (87) 0.91 0.14 1.06 0.65
> 100 257 (69) 0.86 0.33 1.30 0.41
> 200 134 (36) 0.64 0.68 1.98 0.54BMC Infectious Diseases 2007, 7:10 http://www.biomedcentral.com/1471-2334/7/10
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Finally, the rational in our trials was the concept that diag-
nosis is not the principle outcome measure in the tradi-
tional sense of diagnostic test evaluation. Instead, these
intervention studies looked directly at patient outcomes,
assuming that if the patient recovered without antibiotics
then there was no serious bacterial illness. Although not
being a new "gold standard", this circumvented the prob-
lem of the non-existent diagnostic "gold standard" to
decide on the presence or absence of a clinically relevant
bacterial infection based on traditional criteria.
Conclusion
In conclusion, signs and symptoms routinely attributed to
CAP are of limited value for the diagnosis of CAP. PCT
and hsCRP can improve the diagnostic value of the clini-
cal assessment. If confirmed, both parameters may, thus,
be considered to replace leukocyte count in future guide-
lines of CAP. PCT has the highest diagnostic accuracy in
differentiating radiographically confirmed CAP from
other differential diagnoses, to predict bacteremia and to
assess the severity of CAP.
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